ERBB2 and breast carcinoma: Such co-amplification suggests the proposed HER2–uPAR cooperativity as being specific to an early-stage aggressive breast carcinoma subtype and may partially explain the failure of existing HER2-targeted therapies and drug resistance, thereby indicating these receptors as potential synergistic targets for therapeutic intervention [154].